• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CXCR4 过度激活与 TCL1 共同促进 CLL 的发展和侵袭性。

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

机构信息

Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

School of Medicine, Technische Universität München, Munich, Germany.

出版信息

Leukemia. 2021 Oct;35(10):2895-2905. doi: 10.1038/s41375-021-01376-1. Epub 2021 Aug 6.

DOI:10.1038/s41375-021-01376-1
PMID:34363012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8478649/
Abstract

Aberrant CXCR4 activity has been implicated in lymphoma pathogenesis, disease progression, and resistance to therapies. Using a mouse model with a gain-of-function CXCR4 mutation (CXCR4) that hyperactivates CXCR4 signaling, we identified CXCR4 as a crucial activator of multiple key oncogenic pathways. CXCR4 hyperactivation resulted in an expansion of transitional B1 lymphocytes, which represent the precursors of chronic lymphocytic leukemia (CLL). Indeed, CXCR4 hyperactivation led to a significant acceleration of disease onset and a more aggressive phenotype in the murine Eµ-TCL1 CLL model. Hyperactivated CXCR4 signaling cooperated with TCL1 to cause a distinct oncogenic transcriptional program in B cells, characterized by PLK1/FOXM1-associated pathways. In accordance, Eµ-TCL1;CXCR4 B cells enriched a transcriptional signature from patients with Richter's syndrome, an aggressive transformation of CLL. Notably, MYC activation in aggressive lymphoma was associated with increased CXCR4 expression. In line with this finding, additional hyperactive CXCR4 signaling in the Eµ-Myc mouse, a model of aggressive B-cell cancer, did not impact survival. In summary, we here identify CXCR4 hyperactivation as a co-driver of an aggressive lymphoma phenotype.

摘要

异常的 CXCR4 活性已被牵涉到淋巴瘤的发病机制、疾病进展和对治疗的耐药性中。我们使用一种具有功能获得性 CXCR4 突变(CXCR4)的小鼠模型,该突变可过度激活 CXCR4 信号,将 CXCR4 鉴定为多个关键致癌途径的关键激活剂。CXCR4 的过度激活导致过渡性 B1 淋巴细胞的扩增,而过渡性 B1 淋巴细胞是慢性淋巴细胞白血病(CLL)的前体。事实上,CXCR4 的过度激活导致了小鼠 Eµ-TCL1 CLL 模型中疾病发病的显著加速和更具侵袭性的表型。过度激活的 CXCR4 信号与 TCL1 合作,导致 B 细胞中出现独特的致癌转录程序,其特征是与 PLK1/FOXM1 相关的途径。相应地,Eµ-TCL1;CXCR4 B 细胞富集了来自 Richter 综合征患者的转录特征,Richter 综合征是 CLL 的一种侵袭性转化。值得注意的是,侵袭性淋巴瘤中 MYC 的激活与 CXCR4 表达的增加有关。与这一发现一致,Eµ-Myc 小鼠(一种侵袭性 B 细胞癌模型)中额外的过度激活的 CXCR4 信号并不影响生存。总之,我们在这里确定 CXCR4 的过度激活是侵袭性淋巴瘤表型的共同驱动因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/f0748b69085a/41375_2021_1376_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/0699f7bc3bc4/41375_2021_1376_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/8766affe1641/41375_2021_1376_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/3ee5a566fc6a/41375_2021_1376_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/c86dcfc4cafb/41375_2021_1376_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/f0748b69085a/41375_2021_1376_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/0699f7bc3bc4/41375_2021_1376_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/8766affe1641/41375_2021_1376_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/3ee5a566fc6a/41375_2021_1376_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/c86dcfc4cafb/41375_2021_1376_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7a/8478649/f0748b69085a/41375_2021_1376_Fig5_HTML.jpg

相似文献

1
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.CXCR4 过度激活与 TCL1 共同促进 CLL 的发展和侵袭性。
Leukemia. 2021 Oct;35(10):2895-2905. doi: 10.1038/s41375-021-01376-1. Epub 2021 Aug 6.
2
Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.对小鼠 CLL 的纵向分析确定了与白血病相关的克隆变化,包括 Myc 增益,这预示着患者的预后不良。
Leukemia. 2022 Feb;36(2):464-475. doi: 10.1038/s41375-021-01381-4. Epub 2021 Aug 20.
3
PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.PTPROt介导的p53/Foxm1调控在慢性淋巴细胞白血病小鼠模型中抑制白血病表型。
Leukemia. 2015 Jun;29(6):1350-9. doi: 10.1038/leu.2014.341. Epub 2014 Dec 8.
4
Lessons learned from the Eµ-TCL1 mouse model of CLL.从 Eµ-TCL1 小鼠模型中得到的慢性淋巴细胞白血病研究经验。
Semin Hematol. 2024 Jun;61(3):194-200. doi: 10.1053/j.seminhematol.2024.05.002. Epub 2024 May 10.
5
PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).PIM 激酶对于慢性淋巴细胞白血病细胞的存活(PIM2/3)和 CXCR4 介导的微环境相互作用(PIM1)是必不可少的。
Mol Cancer Ther. 2014 May;13(5):1231-45. doi: 10.1158/1535-7163.MCT-13-0575-T. Epub 2014 Mar 21.
6
miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.在Eµ-TCL1小鼠模型中,miR-181b作为慢性淋巴细胞白血病的治疗剂。
Oncotarget. 2015 Aug 14;6(23):19807-18. doi: 10.18632/oncotarget.4415.
7
Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.基质细胞调节 TCL1 的表达,在慢性淋巴细胞白血病中与 AP-1 成分和 TCL1 靶向 microRNAs 相互作用。
Leukemia. 2012 Aug;26(8):1812-20. doi: 10.1038/leu.2012.63. Epub 2012 Mar 5.
8
Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.微环境诱导的 PIM 激酶促进了 CXCR4 触发的 mTOR 通路,该通路对于慢性淋巴细胞白血病细胞的迁移是必需的。
J Cell Mol Med. 2018 Jul;22(7):3548-3559. doi: 10.1111/jcmm.13632. Epub 2018 Apr 17.
9
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.活跃的 Akt 信号通过过度激活 Notch1 触发 CLL 向 Richter 转化。
Blood. 2021 Feb 4;137(5):646-660. doi: 10.1182/blood.2020005734.
10
CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.TCL1 转基因小鼠中的 CD5+CD23+白血病细胞群体表现出明显增加的增殖和 Akt 磷酸化。
Leukemia. 2010 May;24(5):970-5. doi: 10.1038/leu.2010.46. Epub 2010 Apr 1.

引用本文的文献

1
[Establishment of a chronic lymphocytic leukemia mouse model via adoptive transfer of Eμ-TCL1 transgenic splenocytes].[通过Eμ-TCL1转基因脾细胞的过继转移建立慢性淋巴细胞白血病小鼠模型]
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):445-452. doi: 10.3760/cma.j.cn121090-20241120-00461.
2
Molecular Features Accompanying Richter's Transformation in Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病患者里氏转化伴随的分子特征
Int J Mol Sci. 2025 Jun 10;26(12):5563. doi: 10.3390/ijms26125563.
3
CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment.

本文引用的文献

1
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.活跃的 Akt 信号通过过度激活 Notch1 触发 CLL 向 Richter 转化。
Blood. 2021 Feb 4;137(5):646-660. doi: 10.1182/blood.2020005734.
2
Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.伴血液学紊乱的 Cxcr4 功能获得性突变导致不受控制的滤泡外免疫反应。
Blood. 2021 Jun 3;137(22):3050-3063. doi: 10.1182/blood.2020007450.
3
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
CXCR家族与骨髓微环境中的血液系统恶性肿瘤
Biomolecules. 2025 May 13;15(5):716. doi: 10.3390/biom15050716.
4
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?慢性淋巴细胞白血病中的肿瘤细胞存活因子与血管生成:二者关联有多紧密?
Cancers (Basel). 2024 Dec 29;17(1):72. doi: 10.3390/cancers17010072.
5
Proliferating CLL cells express high levels of CXCR4 and CD5.增殖性慢性淋巴细胞白血病细胞表达高水平的CXCR4和CD5。
Hemasphere. 2024 Dec 17;8(12):e70064. doi: 10.1002/hem3.70064. eCollection 2024 Dec.
6
PET imaging of CXCR4 expression using [F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors.使用 [F]AlF-NOTA-QHY-04 进行 CXCR4 表达的 PET 成像,用于血液恶性肿瘤和实体肿瘤。
Theranostics. 2024 Sep 30;14(16):6337-6349. doi: 10.7150/thno.99025. eCollection 2024.
7
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.慢性淋巴细胞白血病发病机制中的B细胞受体信号传导及相关通路
Front Oncol. 2024 Feb 26;14:1339620. doi: 10.3389/fonc.2024.1339620. eCollection 2024.
8
CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study.慢性淋巴细胞白血病中 CXCR4 的过表达与预后不良相关:一项前瞻性、单中心、观察性研究。
Genes Immun. 2024 Apr;25(2):117-123. doi: 10.1038/s41435-024-00258-7. Epub 2024 Feb 17.
9
Biology and Treatment of Richter Transformation.里氏转化的生物学特性与治疗
Front Oncol. 2022 Mar 22;12:829983. doi: 10.3389/fonc.2022.829983. eCollection 2022.
10
The Modes of Dysregulation of the Proto-Oncogene T-Cell Leukemia/Lymphoma 1A.原癌基因T细胞白血病/淋巴瘤1A的失调模式
Cancers (Basel). 2021 Oct 29;13(21):5455. doi: 10.3390/cancers13215455.
慢性淋巴细胞白血病中 Richter 转化的基因组和转录组相关性。
Blood. 2021 May 20;137(20):2800-2816. doi: 10.1182/blood.2020005650.
4
Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia.B 细胞中的病理性 RANK 信号转导导致自身免疫和慢性淋巴细胞白血病。
J Exp Med. 2021 Feb 1;218(2). doi: 10.1084/jem.20200517.
5
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.塔西美替尼治疗复发或难治性滤泡性淋巴瘤患者的疗效:一项开放标签、单臂、多中心、2 期临床试验。
Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6.
6
The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.BLIMP1-EZH2 轴在非霍奇金淋巴瘤中的作用。
Oncogene. 2020 Jul;39(28):5138-5151. doi: 10.1038/s41388-020-1347-8. Epub 2020 Jun 12.
7
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma.CXCR4 靶向 PET 成像在中枢神经系统 B 细胞淋巴瘤中的应用。
J Nucl Med. 2020 Dec;61(12):1765-1771. doi: 10.2967/jnumed.120.241703. Epub 2020 Apr 24.
8
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.CXCR4 的上调是对 B 细胞受体/PI3K 阻断敏感的一个指标,也是 B 细胞受体依赖性弥漫性大 B 细胞淋巴瘤潜在的耐药机制。
Haematologica. 2020 May;105(5):1361-1368. doi: 10.3324/haematol.2019.216218. Epub 2019 Aug 30.
9
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.一项多中心 1 期研究:plerixafor 联合利妥昔单抗治疗慢性淋巴细胞白血病。
Leuk Lymphoma. 2019 Dec;60(14):3461-3469. doi: 10.1080/10428194.2019.1643463. Epub 2019 Jul 27.
10
RNA sequencing identifies clonal structure of T-cell repertoires in patients with adult T-cell leukemia/lymphoma.RNA测序鉴定成人T细胞白血病/淋巴瘤患者T细胞受体库的克隆结构。
NPJ Genom Med. 2019 May 6;4:10. doi: 10.1038/s41525-019-0084-9. eCollection 2019.